Administration of first immunotherapy drug in MIO, raises hopes for cancer victims
- ‘Durvalumab’, the first immunotherapy drug for stage III lung cancer (that has not progressed after chemo-radiation treatment), was given to a woman for the first time in this region at Mangalore Institute of Oncology (MIO) recently.
- “Durvalumab, an immunotherapy drug approved by FDA (food and drug administration) in 2018, is being used for the first time as a curative option in this region,”
